Modeling multi-drug chemotherapy: tailoring treatment to individuals.
暂无分享,去创建一个
[1] D. Lacombe,et al. Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] G. Bonadonna,et al. Cell proliferation and outcome following doxorubicin plus CMF regimens in node‐positive breast cancer , 2000 .
[3] Xin Xie,et al. The prognostic value of spontaneous apoptosis, Bax, Bcl‐2, and p53 in oral squamous cell carcinoma of the tongue , 1999, Cancer.
[4] G. Mathé. The kinetics of cancer cells and of HIV1: the problems of cell and virus rebounds and of latency. , 1998, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[5] A. D. Schryver,et al. Systemic treatment of early breast-cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women: 1 , 1992 .
[6] R. Hoffman,et al. Hematology: Basic Principles and Practice , 1995 .
[7] R. Souhami. Will increases in dose intensity improve outcome: con. , 1995, The American journal of medicine.
[8] P. Vaupel,et al. Hypoxic cervical cancers with low apoptotic index are highly aggressive. , 1999, Cancer research.
[9] G. Bonadonna,et al. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. , 1995, JAMA.
[10] F. Landoni,et al. Potentials of cell kinetics in the management of patients with ovarian cancers. , 1992, European journal of cancer.
[11] M. Kattan,et al. Assessment of the biologic markers p53, ki‐67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery , 1998 .
[12] K. Hande,et al. The importance of drug scheduling in cancer chemotherapy: etoposide as an example. , 1996, Stem cells.
[13] J. Leith,et al. Host response in tumor growth and progression. , 1996, Invasion & metastasis.
[14] F. Sinicrope,et al. Apoptotic and mitotic indices predict survival rates in lymph node-negative colon carcinomas. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[15] H. Deeg,et al. HLA-DR-triggered inhibition of hemopoiesis involves Fas/Fas ligand interactions and is prevented by c-kit ligand. , 1997, Journal of immunology.
[16] P. Lipponen. Apoptosis in breast cancer: relationship with other pathological parameters. , 1999, Endocrine-related cancer.
[17] J. Coindre,et al. Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. , 1996, British Journal of Cancer.
[18] H. Skipper,et al. Experimental evaluation of potential anticancer agents. XXI. Scheduling of arabinosylcytosine to take advantage of its S-phase specificity against leukemia cells. , 1967, Cancer chemotherapy reports.
[19] J. Thompson,et al. Mathematical Model For Human Myeloma Relating Growth Kinetics and Drug Resistance , 1986, Cell and tissue kinetics.
[20] U. Veronesi,et al. Changes in biological markers after primary chemotherapy for breast cancers , 1995, International journal of cancer.
[21] R T Schimke,et al. Gene amplification, drug resistance, and cancer. , 1984, Cancer research.
[22] J N Weinstein,et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. , 1997, Cancer research.
[23] S. George,et al. Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study , 1976, Cancer.
[24] W R Greco,et al. Modeling of the time-dependency of in vitro drug cytotoxicity and resistance. , 1998, Cancer research.
[25] Goldie Jh,et al. Impact of dose-intense chemotherapy on the development of permanent drug resistance. , 1987 .
[26] G. Hortobagyi,et al. Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] C. Karapetis,et al. Matrix Metalloproteinase Inhibitors: Applications in Oncology , 2004, Investigational New Drugs.
[28] J. Meyer. Measurements of Cellular Proliferation and DNA in Breast Carcinoma , 1989 .
[29] T. Graeber,et al. Selection of human cervical epithelial cells that possess reduced apoptotic potential to low-oxygen conditions. , 1997, Cancer research.
[30] L. A. Price. Safer cancer chemotherapy using a kinetically-based experimental approach: higher dose intensity with reduced toxicity. , 1987, Cancer treatment reviews.
[31] H. Mouridsen,et al. Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer--a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group. Danish Breast Cancer Cooperative Group (DBCG , 1999, European journal of cancer.
[32] J. Carey. DEMOGRAPHY AND POPULATION DYNAMICS OF THE MEDITERRANEAN FRUIT FLY , 1982 .
[33] K. Alitalo. Amplification of cellular oncogenes in cancer cells. , 1985, Medical biology.
[34] F Pozza,et al. Breast cancer cell kinetics: immunocytochemical determination of growth fractions by monoclonal antibody Ki-67 and correlation with flow cytometric S-phase and with some features of tumor aggressiveness. , 1991, Anticancer research.
[35] M Gyllenberg,et al. Quiescence as an explanation of Gompertzian tumor growth. , 1989, Growth, development, and aging : GDA.
[36] V. Jordan,et al. Endocrine pharmacology of antiestrogens as antitumor agents. , 1990, Endocrine reviews.
[37] M. Province,et al. Proliferative rate by S‐phase measurement may affect cure of breast carcinoma , 1995, Cancer.
[38] M. Goldenberg. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. , 1999, Clinical therapeutics.
[39] G. Bevilacqua,et al. Primary chemotherapy in locally advanced breast cancer (LABC): effects on tumour proliferative activity, bcl-2 expression and the relationship between tumour regression and biological markers. , 1998, European journal of cancer.
[40] B. Tibken,et al. Chapter 7: Biomathematical engineering of cell renewal systems: An approach to a biomathematical model of lymphocytopoiesis , 1995, Stem cells.
[41] S N Gardner,et al. A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and -nonspecific drugs. , 2000, Cancer research.
[42] G. Gudauskas,et al. 5-FU infusion in advanced colorectal cancer: a comparison of three dose schedules. , 1985, Cancer treatment reports.
[43] L. Norton,et al. The Norton-Simon hypothesis revisited. , 1986, Cancer treatment reports.
[44] J. Ragaz,et al. High-Risk Breast Cancer , 1989, Springer Berlin Heidelberg.
[45] D Tripathy,et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] James H. Goldie,et al. Drug Resistance in Cancer: Mechanisms and Models , 1998 .
[47] Mike Clarke,et al. Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.
[48] B. Stenkvist,et al. Appearance of amplified thymidylate synthase or dihydrofolate reductase genes in stage‐IV breast‐cancer patients receiving endocrine treatment , 1993, International journal of cancer.
[49] R. Greenberg,et al. Geometry, growth rates, and duration of cancer and carcinoma in situ of the breast before detection by screening. , 1986, Cancer research.
[50] R. Silvestrini,et al. Cell kinetics and response to primary intra-arterial chemotherapy in patients with advanced oral cavity tumors. , 1991, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.
[51] C. Townsend,et al. Treatment-induced changes in sensitivity in a multiclonal human tumor mixture model in vitro. , 1988, Cancer research.
[52] J. Panetta,et al. A mathematical model of drug resistance: heterogeneous tumors. , 1998, Mathematical biosciences.
[53] J. Bertino,et al. Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] L. Norton,et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. , 1994, The New England journal of medicine.
[55] R. Day,et al. Treatment sequencing, asymmetry, and uncertainty: protocol strategies for combination chemotherapy. , 1986, Cancer research.
[56] S Gallivan,et al. A mathematical model of the development of drug resistance to cancer chemotherapy. , 1987, European journal of cancer & clinical oncology.
[57] K. Jabboury,et al. Cell proliferation kinetics of normal and tumour tissue in vitro: quiescent reproductive cells and the cycling reproductive fraction , 1995, Cell proliferation.
[58] F. Goldstein,et al. Consequences of increasing resistance to antimicrobial agents. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[59] J S Spratt,et al. Decelerating growth and human breast cancer , 1993, Cancer.
[60] Z Bajzer,et al. Analysis of growth of multicellular tumour spheroids by mathematical models , 1994, Cell proliferation.
[61] L. Putten,et al. ARE CELL KINETIC DATA RELEVANT FOR THE DESIGN OF TUMOUR CHEMOTHERAPY SCHEDULES? * , 1974 .
[62] L. Norton. A Gompertzian model of human breast cancer growth. , 1988, Cancer research.
[63] Z. Agur,et al. The dynamics of gene amplification described as a multitype compartmental model and as a branching process. , 1991, Mathematical biosciences.
[64] K. Ang,et al. Heterogeneity in the development of apoptosis in irradiated murine tumours of different histologies. , 1993, International journal of radiation biology.
[65] I. Tannock,et al. Cell kinetics and chemotherapy: a critical review. , 1978, Cancer treatment reports.
[66] A. Goldhirsch,et al. Prediction of response to primary chemotherapy for operable breast cancer. , 1999, European journal of cancer.
[67] C. Hudis,et al. Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] H M Byrne,et al. Growth of nonnecrotic tumors in the presence and absence of inhibitors. , 1995, Mathematical biosciences.
[69] T. Kitamura,et al. Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation , 1999, Cancer.
[70] J. Leith,et al. Changes in the extents of viable and necrotic tissue, interstitial fluid pressure, and proliferation kinetics in clone A human colon tumour xenografts as a function of tumour size , 1994 .
[71] M. Brizzi,et al. Cytotoxic and antiproliferative activity of the CMF regimen administered in association with tamoxifen as primary chemotherapy in breast cancer patients. , 1998, International journal of oncology.
[72] Hryniuk Wm. Average relative dose intensity and the impact on design of clinical trials. , 1987, Seminars in oncology.
[73] M. Retsky,et al. A stochastic numerical model of breast cancer growth that simulates clinical data. , 1984, Cancer research.
[74] S. Michelson. Mathematical models for multidrug resistance and its reversal , 2004, Cytotechnology.
[75] S. Gardner. Scheduling Chemotherapy: Catch 22 between Cell Kill and Resistance Evolution , 2000 .
[76] R. P. Falcão,et al. Increased apoptotic cells in bone marrow biopsies from patients with aplastic anaemia , 1997, British journal of haematology.
[77] M. Daidone,et al. Cell proliferation in 3,800 node‐negative breast cancers: Concistency over time of biological and clinical information provided by 3H‐Thymidine labelling index , 1997, International journal of cancer.
[78] L. Norton,et al. Tumor size, sensitivity to therapy, and design of treatment schedules. , 1977, Cancer treatment reports.
[79] P. Rougier,et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[80] Marc Mangel,et al. A revolving dose strategy to delay the evolution of both quantitative vs major monogene resistances to pesticides and drugs , 1998 .